Valeant subpoenaed over pricing; Fidelity manager preaches patience in biotech slump;

@FierceBiotech: Zafgen finally breaks its silence, says it's probing death of a patient. Report | Follow @FierceBiotech

@JohnCFierce: Still trending -- Moderna's top scientist steps down amid a billion-dollar R&D push by @DamianFierce. Article | Follow @JohnCFierce

@DamianFierce: There is perhaps no greater tribute to Steve Jobs than obfuscating your business model and threatening your critics. WSJ story | Follow @DamianFierce

> Federal prosecutors have subpoenaed Valeant Pharmaceuticals ($VRX) for more information on how it prices drugs. Story

> Biotech's recent troubles on Wall Street are part of a "manic-depressive" period that will pass, Fidelity fund manager Rajiv Kaul told Bloomberg. More

> Transition Therapeutics ($TTHI) said its Alzheimer's disease treatment charted a clinical benefit on a Phase II trial among patients with agitation and aggression related to the disease, despite missing its primary endpoint. News

Medical Device News

@FierceMedDev: Intelesens gets FDA approval for its Zensor wearable vital signs device. More | Follow @FierceMedDev

@VarunSaxena2: California cutbacks: BD cuts 95 at CareFusion; Medtronic to cut 21 at distribution facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. FiercePharma report | Follow @EmilyWFierce

> Astute Medical to launch its diagnostic in China thanks to $20M investment from FosunPharma. Report

> 23andMe adds chapter to comeback story with $115M in funding. Article

Pharma News

@FiercePharma: ICYMI: Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Mylan hopes new show-and-tell will woo Perrigo shareholders. Story | Follow @CarlyHFierce

> Valeant hit with two federal subpoenas as drug-price controversy rages on. Story

> Pfizer CEO: Drug-pricing snafu isn't pharma's fault. It's insurers and their poor coverage. More

> Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. Article

CRO News

> INC bolsters its Phase I platform with new cardiac tech. Story

> Aesica bids to manage its clients' many contractors. More

> Cel-Sci lines up cash to fund its $50M suit against ex-partner inVentiv. Report

> CRO Frontage gets into agrochemicals with new service offering. Story

> PRA adds a biotech vet to its board amid an expansion effort. Article

Pharma Manufacturing News

> Myanmar offers incentives to lure its drug distributors into production. News

> Medline recalls 500 mg acetaminophen labeled as 325 mg. More

> Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs. Report

> Chinese company intends to build plant to produce Ebola vax. Article

> GSK selling its drug distribution biz in Romania. Story

Pharma Asia News

> China's State Council urges Suzhou Industrial Park to be more innovative. Story

> Japanese drug regulator opening Indian office. Item

> Lupin inks deal with Boehringer for diabetes drugs in India. News

> Superbug infections drop in China with new controls on antibiotics. Article

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.